UK-based medical device-maker Inotec, which specialises in wound care, has appointed Craig Kennedy as its new chief executive.

Kennedy (pictured) brings over 25 years of experience in the medical device and pharmaceutical industry, as well as a proven track record of building businesses in the wound care space, including most recently as chief executive of start-up MolecuLight in Toronto, Canada. Prior to this, he was vice president of business development and strategy for Systagenix, and played a key role in the divestiture of that business to Acelity in 2013.

Inotec chairman Dr Adrian Parton commented: “The board of directors are pleased to announce the appointment of Craig Kennedy who will be starting his new role as chief executive of the company in March, and we believe that his extensive global experience of the wound care market will help the company drive the growth of Inotec AMD's novel oxygen therapy products on a global basis.”